The new integration will help bodily treatment clinics automate compliance, enhance reimbursements, and maximize staff efficiency
NASHVILLE, Tenn., April 3, 2023 (Newswire.com)
– PredictionHealth, an Synthetic Intelligence health care technologies enterprise, declared a new partnership with PromptEMR, a following-generation Bodily Treatment observe management application corporation. This partnership will permit Prompt clients to seamlessly leverage PredictionHealth’s PT Practice Intel services, a proprietary AI procedure that analyzes each individual word of each sentence throughout 100{08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f} of therapists’ charts to offer unparalleled visibility into the health of a apply. The intuitive platform offers AI-produced insights to enable automate compliance, optimize reimbursements, and maximize effectiveness.
“The Physical Treatment sector proceeds to experience a slew of worries, specially with continued reimbursement cuts, demanding restrictions, and team burnout and turnover. But we know our product can assist. We are thrilled to include Prompt EMR as a associate to provide their purchasers a resolution to support boost compliance and profits even though streamlining documentation and KPI collecting and reporting. The seamless details feed from Prompt’s strong EMR platform will grant Prompt people obtain to unparalleled insights and will appreciably raise the amount that feed-back reaches apply entrepreneurs, professionals, and therapists.”
-Pedro Teixeira, MD, PhD, CEO and Co-founder of PredictionHealth
“Unsuccessful audits and around-documentation are two issues that have been plaguing the bodily treatment marketplace for many years. PredictionHealth’s superior AI-driven program put together with Prompt’s all-in-one EMR and Exercise Management software package makes a a person-of-a-kind option for sustaining compliance and steering clear of therapist burnout. We are fired up to be signing up for forces to continue to assistance transfer the outpatient rehabilitation industry ahead.“
– Ray Baliatico, CEO of Prompt EMR
About PredictionHealth:
PredictionHealth is a Nashville-based mostly healthcare technology company with a mission to make it simple for clinicians to produce the greatest treatment to just about every affected person each and every time by streamlining clinician workflows and lowering administrative busywork. Founded in 2017 by Pedro Teixeira, MD, PhD, CEO and Ravi Atreya, MD, PhD, CMO, the company has produced AI tool sets leveraging their means to examine unstructured facts to extract meaningful insights from medical documentation. For much more info, you should visit www.predictionhealth.com/.
About Prompt EMR:
Prompt EMR is a absolutely-built-in organization platform that offers end-to-conclusion company administration software program for the Outpatient Rehabilitation field. Prompt’s fashionable, effortless-to-use method streamlines workflows for each consumer in just a clinic, driving improved effectiveness, profitability, and client care. Prompt addresses on-line affected individual scheduling, digital onboarding, in-clinic scheduling, affected individual administration, documentation, billing, reporting, and analytics, making it possible for a clinic to make the most of a person piece of software to regulate their entire enterprise. Prompt EMR’s streamlined workflows eliminate cumbersome facts entry and handbook processes which drives greater clinic profitability, a better affected individual experience, and improved outcomes. For a lot more details, you should visit www.promptemr.com.
In this article, we discuss the 12 biggest health insurance companies in the world. If you want to see more companies in this selection, check out the 5 Biggest Health Insurance Companies in the World.
According to Allied Market Research, the size of the global healthcare insurance industry stood at $1.98 trillion at the end of 2020. The COVID-19 pandemic has resulted in an increased demand for health insurance around the world. The size of the industry is expected to compound annually at an average rate of 9.7{08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f} to reach $4.15 trillion by 2028. People consider health insurance services as an integral tool to share medical costs during accidents, illnesses, and injuries. The impact of the delay in routine healthcare services during the COVID-19 pandemic played favorably for health insurance companies. However, this effect was also offset by the increase in demand for COVID-19-related testing and treatment claims.
The Protection Gap: Addressing Economic Losses in Health Insurance and Beyond
Experts believe that health insurance companies that can innovate and transform their offerings according to customers’ demands will be able to grow during these uncertain times. The uncertainty related to geopolitical and macroeconomic outlook has made business stability the top priority amongst health insurance companies such as Centene Corporation (NYSE:CNC), UnitedHealth Group Incorporated (NYSE:UNH), and Elevance Health, Inc. (NYSE:ELV).
In addition, the protection gap is growing with every passing day as the insurance related to natural disasters, cyber attacks, and health, only partially covers the actual economic losses related to these events. For instance, in 2019, more than 400 natural disaster events resulted in an economic loss of $232 billion, but only $71 billion of the loss was insured. This gap is expected to increase as the global population and life expectancy rise. These factors would provide the health insurance industry with a bigger market to target.
According to the Swiss Re Institute, the insurance industry could increase its bottom line by $60 – $80 billion annually if it works on reducing the insurance protection gaps. As of 2021, the global insurance protection gap stood at $1.4 trillion, while the global health protection gap was estimated at $737 billion. Experts believe the higher government spending on healthcare during the COVID-19 pandemic helped reduce the health protection gap; however, it is expected to increase again as the pandemic has eased and governments around the world are shifting their focus towards other activities. Experts also highlight the low level of insurance literacy as a major challenge in gaining widespread market penetration. According to research conducted by French insurer SCOR, a significant number of people do not purchase insurance because they cannot comprehend the terms and conditions. The study comprised 12,000 consumers from around the world. Governments, regulators, insurance companies, and employers must come together to address the challenges to boost the adoption of health insurance.
12 Biggest Health Insurance Companies in the World
national-cancer-institute-GcrSgHDrniY-unsplash
Our Methodology
We carried out thorough research utilizing a variety of dependable sources, including company and industry reports and financial databases, to determine the largest health insurance companies in the world. We took into account pertinent aspects, like the company’s consumer base, product offerings, business models, and global reach, to assess its scale of operations. The companies have been ranked in ascending order of their trailing twelve months (ttm) revenue. The list includes both private and public limited companies.
MetLife, Inc. (NYSE:MET) is a New York-based provider of annuities, employee benefit programs, and insurance. The company provides a wide range of health insurance products like accident insurance, disability and absence services, hospital indemnity, critical illness, and cancer insurance.
In a research note issued on January 6, Jimmy Bhullar at JPMorgan increased the target price for MetLife, Inc. (NYSE:MET) from $77 to $80 and maintained an Overweight rating on the stock. The analyst anticipates the company’s life and health insurance segment to perform well in 2023 as the benchmark interest rates are expected to rise further. However, this could be offset by a weak economy that could dent demand along with a higher risk of credit losses.
11. Münchener Rückversicherungs-Gesellschaft Aktiengesellschaft in München (MUV2.DE)
TTM Total Revenue: $71.50 billion (€67.09 billion)
Münchener Rückversicherungs-Gesellschaft Aktiengesellschaft in München (MUV2.DE), more commonly known as Munich Re Group, is a German insurance company established in 1880. The company provides a wide variety of reinsurance products related to healthcare.
Munich Re has established an ambitious roadmap for the next five years called the Munich Re Group Ambition 2025. While preserving and reinforcing the core of its business model, the company aims to drive the transition towards new business models. The company plans to enhance its market position in Germany and achieve profitable growth in international business, B2B operations, and direct customer offerings.
10. CVS Health Corporation (NYSE:CVS) [ Owner of Aetna]
TTM Total Revenue (Aetna): $82.2 billion
CVS Health Corporation (NYSE:CVS) is a Woonsocket, Rhode Island-based healthcare company that is also a provider of health insurance services.
The company acquired Aetna in 2018 to expand its presence in the health insurance segment. Based on 2021 total health plan enrollments, CVS Health Corporation (NYSE:CVS) secured the sixth position with 2,574,348 enrollments. In a note issued to investors on February 9, Brian Tanquilut at Jefferies increased the target price for CVS Health Corporation (NYSE:CVS) from $130 to $143 and maintained a Buy rating on the stock following the strong Q4 2022 results. The company also disclosed that it intends to acquire Chicago, Illinois-based healthcare company Oak Street Health, Inc. (NYSE:OSH) for a sum of $10.6 billion. The analyst anticipates the earnings from Oak Street to contribute towards the company’s bottom-line growth after 2024.
Vltava Fund shared its outlook on CVS Health Corporation (NYSE:CVS) in its Q3 2022 investor letter. Here’s what the firm said:
“CVS is a leader in the provision of healthcare services in the USA. It has three main businesses: an enormous network of pharmacies, a health insurance company, and “prescription benefit management”, which is a kind of intermediary between insurance companies and pharmacies. This is the result of large acquisitions over the past 15 years – most notably of Caremark (2007) and Aetna (2018). The markets had deemed its acquisition of health insurer Aetna too expensive (and we agree), so CVS stock then fell into disfavour for a few years.
We took advantage of this in the summer of 2020 and brought the stock into our portfolio at a time when its price was pressed down still further by the coronavirus pandemic. CVS is a giant. It has revenues of USD 300 billion, making it one of the largest companies in the world. It is a relatively stable and highly profitable company with strong free cash flow. Over the past few years, CVS has focused primarily on reducing debt.
This is already much lower than it had been after the Aetna acquisition, and most of the cash is now likely to go to shareholders through share buybacks or be used for smaller acquisitions to grow the company further. CVS trades at about 11 times annual earnings, which is a very appealing valuation given the expected future growth in profitability and overall modest cyclicality in its business.”
Humana Inc. (NYSE:HUM) is a Louisville, Kentucky-based health insurance company founded in 1961.
The corporation occupies the 114th position on the 2023 America’s Best Large Employers list curated by Forbes. Furthermore, based on the total health plan enrollment data for 2021 compiled by Forbes, Humana Inc. (NYSE:HUM) is the 11th biggest health insurance company in the US, with an enrollment of 887,612 members. Following the Q4 2022 results, George Hill at Deutsche Bank assigned Humana Inc. (NYSE:HUM) stock a target price of $562 along with a Buy rating on February 28. The analyst highlighted the company’s decision to exit the Employer Group Commercial Medical Products business company. The business segment included the Federal Employee health benefit plans and rewards programs that are fully insured and self-funded.
“In September, We added a new position in the Health Care sector with Humana Inc. (NYSE:HUM), one of the largest managed care providers in the U.S. with a focus on medical insurance for the Medicare Advantage market. We believe Humana is poised to see a reacceleration in Medicare Advantage membership growth after making large investments in its program benefits earlier this year. In addition, we like the demographic tailwinds for the entire Medicare Advantage market, as the next four years should provide the highest number of baby boomers yet qualifying for Medicare benefits.”
9. Kaiser Permanente
TTM Total Revenue: $95.4 billion
Kaiser Permanente is an Oakland, California-based healthcare organization founded in 1945.
The company provides a variety of healthcare services, including health insurance, to individuals and families. Kaiser Permanente is a managed care organization, which means that it provides healthcare services through a network of doctors, hospitals, and other healthcare providers. Kaiser Permanente health insurance plans typically offer a range of benefits, including preventative care, medical treatment, prescription drug coverage, and other health services. Some plans may also include dental and vision care. The company occupied the first position in terms of total health plan enrollment in 2021, with 8,228,765 accounts.
8. AXA SA (CS.PA)
TTM Total Revenue: $103.7 billion (€97.25 billion)
AXA SA (CS.PA) is a Paris, France-based insurance company that was founded in 1946. The company has a presence in 50 countries and a headcount of 149,000 employees and distributors. AXA SA (CS.PA) provides insurance and financial management services to 95 million clients around the world.
AXA health insurance plans vary by region and country, but they generally offer a range of benefits, such as hospitalization, outpatient services, preventative care, and prescription drug coverage. The company also offers additional benefits, such as dental and vision care, alternative medicine, and wellness programs. Some plans may also provide coverage for pre-existing conditions, depending on the specific policy. CEO Thomas Buberl shared that in 2023, AXA SA (CS.PA) aims to achieve continuous growth in earnings, propelled by all regions, and a transparent route to increasing dividends. This will be backed by improved cash flow and prudent capital management. AXA SA (CS.PA) stock offers an attractive dividend yield of 5.78{08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f} as of March 13.
6. China Life Insurance Company Limited (601628.SS)
TTM Total Revenue: $115.98 billion (¥804.12 billion)
China Life Insurance Company Limited (601628.SS) is a Beijing, China-based provider of health insurance and other annuities products founded in 2003.
The company has a headcount of 103,262 employees and ranks at the 71st position in the Forbes Global 2000 list for 2022. The Forbes Global 2000 list ranks the biggest companies globally based on revenue, earnings, total assets, and market capitalization. China Life Insurance Company Limited (601628.SS) claims that once a consumer enrolls in the voluntary health insurance services successfully, the company will continue to renew the plan till 100 years of age without taking into consideration the underlying health condition of the insured person or the historical claim record. The company also provides annual coverage of $10,191 (HKD 80,000) for prescribed diagnostic imaging tests, psychiatric treatments, and prescribed non-surgical cancer treatments.
In addition to China Life Insurance Company Limited (601628.SS), companies such as Centene Corporation (NYSE:CNC), UnitedHealth Group Incorporated (NYSE:UNH), and Elevance Health, Inc. (NYSE:ELV) are also some of the biggest health insurance companies in the world.
A new American Medical center Association report can take a closer seem at the most significant challengers to healthcare’s status quo, and worries conventional companies to be revolutionary to endure in a competitive primary care current market.
The most important care landscape, which accounts for some $260 billion in yearly health care expending, is ripe for transformation. The progress of immediate-to-shopper telehealth and the retail healthcare business are putting conventional providers on notice: Embrace innovation or fade absent as individuals take their health care elsewhere.
To have an understanding of how to present key treatment in this chaotic landscape, healthcare leaders may do very best to glimpse at how disruptors are getting into the area. That’s the gist of a report from the American Clinic Affiliation, which cites a Bain & Firm investigation that suggests 30{08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f} of that main care marketplace could be owned by all those non-common providers inside of 7 a long time.
The AHA’s “Well being Care Disruption: 2023 Outlook” examines how seven of the most significant disruptors–Amazon, CVS Well being, UnitedHealth Group, the Walgreens Boots Alliance, and Walmart, and tech providers Apple and Google/Alphabet—has staked their claim in major treatment, and applied that platform to extend.
“The nation’s biggest retail, payer and tech disruptors at the time again invested billions of dollars in health care in 2022, continuing to construct out their visions to remodel the industry,” the report notes. “In the small time period, these moves helped the providers grab industry share in most important care, concierge drugs, virtual treatment, in-residence medical solutions and somewhere else.”
“In quite a few situations, the investments helped organizations broaden their footprints as they go on to combine their growing vertical health care functions in areas like pharmacy gains administration, behavioral wellness, treatment coordination, diagnostics and therapeutics, and wellness information engineering,” the report continues.
It details out that these disruptors are seeing accomplishment by addressing agony factors and gaps in health care that common, cost-for-services companies have failed to right. And in the long term, health care will carry on to see these innovative care styles that aim on worth-based care by, amongst other factors, featuring multi-disciplinary expert services that handle particular customer considerations at the time, put, and modality that they like.
The Disruptors
Amazon may possibly be the most important of the disruptors, with its proposed invest in of A single Health-related, pending a evaluate by the US Federal Trade Commission, poised to substantially shake up the major care discipline. But the on the internet huge is also growing its pharmacy base with RxPass, and boosting diagnostics, therapeutics and illness management capabilities.
But this route forward is not confident, or simple. The failure of the company’s virtual principal care platform, Amazon Care, is however clean, and the A person Clinical partnership is still below critique. Critics also question no matter if Amazon can forge partnerships with wellbeing systems and scale its primary care services to remain on par with rivals like Walgreens and CVS.
CVS Wellbeing, in the meantime, is laying the groundwork to be the greatest main care supplier, capped off by the latest acquisition of Oak Road Well being. The organization has also picked up Signify Well being and is investing closely in digital treatment and electronic wellness, by both equally its HealthHUB places and innovative begin-ups and early-phase tech providers. With far more than 10,000 retail pharmacies in the US and Puerto Rico, as nicely as 1,000 MinuteClinics, it is poised to continue advancement.
But will the company’s achieve exceed its grasp? Critics question if it truly is escalating far too quickly, and not laying the proper groundwork via partnerships with vendors and payers. Management’s goal to facilitate 65 billion healthcare transactions by 2030 is a lofty assure.
UnitedHealth Team, which consists of Optum, is the one familiar face in the crowd, with a qualifications in the payer marketplace. The company has designed a huge force toward diversification, topped off by the $8 billion merger with Transform Health care this earlier calendar year and investments in digital wellness, care coordination and remote client checking capabilities. Now it is focused on price-based mostly care, like an ACO partnership with Walmart, a partnership with HealthEdge and the acquisition of Imperium Well being.
And even though value-based mostly treatment is at the best of everyone’s to-do record, no a person has figured out how to make it get the job done just nevertheless. UnitedHealth Group will have to integrate all of these new partners and applications while also convincing its doctors and customers to embrace VBC.
Walgreens Boots Alliance’s development is nevertheless to arrive, but the organization has laid the ground operate with its partnership with principal care company VillageMD and household care organization CareCentrix and the acquisition of Summit Overall health. The enterprise is now poised to develop its presence in the US with co-situated key care tactics together with its pharmacy community, although building out a home health care system.
The big query is regardless of whether Walgreens Boots can contend with the likes of Amazon and Walmart and fulfill its formidable progress ideas. This is uncharted territory for the company, and the greatest-laid ideas never normally come to fruition.
Walmart, in the meantime, is setting up on an founded foundation as the nation’s most significant retailer by incorporating digital treatment, a price cut drug platform and even an EHR. The corporation is betting on its brand and its pharmacies to create extended-phrase healthcare partnerships, which will be augmented by telehealth companies, wellbeing centers and increased benefit-primarily based treatment partnerships. The vital to its development is in developing partnerships with people.
But the name and the network would not immediately lead to good results. Walmart nevertheless has to provide the sort of health care working experience that will make prospects appear back again all over again and once more. Like the other folks, it will have to scale appropriately, and hope it has the assets to guidance its vision.
Along with the five retail giants are two technology corporations, Apple and Google/Alphabet.
Although Apple won’t be competing for primary care, the company is aggressively increasing its healthcare system through products with the Apple Enjoy and Iphone, providing payers, vendors and scientists new alternatives to hook up with the client. As Apple carries on on this path, it will will need to make confident that connection is secure and reliable. The info collected by all those products and applied by the two people and companies has to accurate, significant and secured, as effectively as quick to assemble and disseminate.
To grow from that system, Apple will need to look for other approaches to monetize that relationship beyond machine product sales.
Google/Alphabet has that platform, and will be investing intensely in AI technological innovation and hardware to make healthcare details accessible and straightforward to use. The firm is actively courting the pharma marketplace and investing in technologies that permits health care organizations to target on wellness fairness, worth-centered treatment and affected person engagement. It can be also partnering with health units to tackle specific agony points like radiology help and affected individual movement.
The question for Google/Alphabet will be regardless of whether it can “personal” the consumer’s healthcare journey and monetize those interactions. Some speculate if the corporation will expand to include things like direct care or prescription prescription drugs.
How Can Health care Corporations Healthy In?
The AHA report concludes with 4 thoughts that just about every health care firm must request:

Do we have an omnichannel presence that delivers the usefulness, obtain, transparency, pricing and other details and providers that sufferers want?

Are there partnership possibilities with any of the Major 5 firms transforming main care?

How can we leverage our power in recognized rely on and rapport with current people to use our outpatient, clinic and virtual solutions for schedule and nonemergent treatment?

How can we partner with big tech companies around research, knowledge sharing, etcetera., to strengthen care?

The implication is clear. Healthcare organizations cannot go on with a business enterprise-as-regular solution. Buyers are much more in management of their health care charges and choices, and they have the potential to shop all over. Furthermore, payers and self-insured corporations are searching for far better means to produce and observe health care, with the objective of slicing out the remarkable total of squander that the marketplace has been supporting for yrs.
In purchase to hold up with the disruptors, they may perhaps have to be the disruptors.
Eric Wicklund is the Innovation and Technological innovation Editor for HealthLeaders.
Beginning on July 1, Medicare enrollees who acquire their insulin by way of a pump as aspect of the Portion B sturdy health-related devices reward will not have to shell out a deductible and they will also profit from the $35 copay cap.
Another provision of the new legislation phone calls for some high-priced medication to be matter to value negotiation with drugmakers. So while the every month most copay for insulins lined by Medicare will be $35 in 2023, 2024 and 2025, beginning in 2026 — the 1st calendar year negotiated selling prices will acquire outcome — lined insulin copays for any medications that have been element of the new negotiations will be $35 or 25 {08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f} of the negotiated rate, whichever is significantly less.
Totally free vaccines
Also underneath the new regulation, vaccines recommended for grownups by the Centers for Illness Management and Prevention’s Advisory Committee on Immunization Methods (ACIP) will be accessible to Medicare recipients absolutely free of charge.
Some vaccines are covered under Section B and are currently absolutely free to Medicare enrollees. Other individuals are lined by Component D prescription drug ideas and call for beneficiaries to shell out some of the price.
For illustration, photographs for the flu, pneumonia, COVID-19 (first pictures and boosters) and hepatitis B for some enrollees are absolutely free beneath Part B and that protection will proceed in 2023. Aspect B also addresses vaccines desired to take care of particular accidents or if you have direct exposure to a sickness. These contain hepatitis A, rabies and tetanus.
Other vaccines, most notably the two-dose Shingrix, which guards towards shingles, are lined less than Aspect D prescription drug designs and could involve expense sharing relying on the plan. Shingrix, for example, can operate as substantially as $200 a dose. Commencing in 2023, even if a beneficiary has not content their Element D deductible, that vaccine and other individuals proposed by ACIP will be totally free to beneficiaries.
Drugmakers experience penalties for substantial selling price hikes
An additional provision of the new legislation that will be thoroughly successful in 2023 necessitates pharmaceutical suppliers to pay out a rebate to Medicare if they raise the selling prices of their medication a lot more than the amount of basic inflation.
Starting in 2023, corporations that market place both equally Aspect D prescription medicines — those acquired at pharmacies — and Element B prescription drugs, usually administered in doctor’s offices, will facial area penalties if they boost costs extra than the amount of inflation. The rebates the corporations owe will be the amount of money they elevated a drug’s value earlier mentioned an maximize to equivalent inflation, multiplied by what Medicare paid out for all gross sales of that drug.
This new prerequisite is supposed to discourage drug firms from increasing their rates earlier mentioned inflation. In accordance to analysis from the nonpartisan Kaiser Family members Foundation, from 2019 to 2020 the costs of half of all drugs coated by Medicare improved far more than the price of inflation.
Beginnings of selling price negotiations
By Sept. 1, Medicare will announce the first 10 Component D drugs that underneath the new legislation will start out a to start with-ever process in which Medicare will negotiate prices with drugmakers, Seshamani mentioned, and that “will have a massive affect for delivering far more affordability for medicines for men and women with Medicare.”
Negotiated prices for that first team of drugs, which will be chosen from the 50 medicines for which Medicare prescription drug programs invest the most, will take influence in 2026.
Some telehealth principles will improve
In the course of the pandemic, Medicare expanded the availability of telehealth. This bundled allowing for patients to converse to suppliers by phone, not just on facial area-to-face movie phone calls, which is what Medicare rules had required. The govt also expanded the kinds of suppliers who would be out there for telehealth visits, together with physical, occupational and speech therapists.
Expanding these additional solutions and the way telehealth visits can be held was made achievable due to the fact Medicare officers ended up in a position to briefly waive present guidelines because of to the coronavirus general public wellness crisis. But the moment the crisis declaration is lifted, many of these added expert services will be out there only for another 151 days, Seshamani says. Congress would have to act to extend these pandemic expansions or make them long lasting.
One spot exactly where the new telehealth flexibilities have been produced long-lasting is behavioral wellness. Beneficiaries will go on to be ready to entry these visits by using telephone only, in addition to via movie.
Improved emphasis on behavioral wellness
“There’s a ton coming in conditions of mobilizing the behavioral wellbeing workforce,” Seshamani states.
Medicare will be paying out for licensed medical social workers, psychologists and other behavioral health professionals to be element of a beneficiary’s main treatment office take a look at “so that they can get their behavioral wellbeing companies suitable there, so that the whole person is taken care of,” Seshamani claims. The program will also make improvements to accessibility to certified relationship and loved ones therapists.
In addition, Medicare is going to increase its expert services for substance abuse. “We are heading to be paying for mobile vans, for illustration, for opioid cure to convey care to where by people are,” Seshamani says.
Some entry to dental care
Medicare does not address regimen dental treatment. It does shell out for some dental work that is needed in conjunction with one more health care process, these as pulling a tooth all through jaw operation. Commencing in 2023, the application will grow the form of “medically necessary” dental solutions it will deal with when desired with other strategies, these kinds of as a cleansing or other dental work that will improve the result of an organ transplant or cancer cure.
Enrollment accessibility improved
Starting in January, as prolonged as people eligible for Medicare enroll in the course of formal enrollment durations, they will not have to hold out for their coverage to acquire outcome. Also beneath a new federal regulation, more special enrollment windows have been founded, such as for people who, through no fault of their have, didn’t signal up when they had been very first suitable.
Prior to this new rule, men and women who signed up for Medicare right after they were intended to — usually in just 3 months of turning 65 — in some cases had to wait around two or three months for coverage to kick in. For case in point, signing up for the duration of the standard enrollment time period (Jan. 1 to March 31) intended waiting around for protection to start off in July.
Commencing in 2023, as prolonged as you utilize for Medicare through either the normal enrollment time period or in the course of a exclusive enrollment period of time, your protection will consider effect at the commencing of the next thirty day period.
Individuals suitable for some of the new specific enrollment durations contain: people who missed their initial enrollment interval due to the fact they ended up afflicted by a all-natural disaster and individuals who ended up offered lousy info from an employer that led them not to indicator up when they were supposed to. In addition, people today who no extended qualify for Medicaid, the federal-condition overall health insurance coverage program for low-cash flow people, will be equipped to apply for Medicare through a specific enrollment interval if they drop their Medicaid protection. Seshamani explained this will be specially critical when the COVID-19 public health emergency is lifted.
Dena Bunis handles Medicare, wellbeing care, health plan and Congress. She also writes the Medicare Built Simple column for the AARP Bulletin. An award-winning journalist, Bunis spent many years operating for metropolitan day by day newspapers, including as Washington bureau main for TheOrange County Register and as a wellbeing policy and place of work writer for Newsday.
In this article, we will take a look at the 15 biggest medical device companies in the world. If you want to skip our introduction to the industry, then take a look at 5 Biggest Medical Device Companies in the World.
The medical device market comprises companies that manufacture equipment used in diagnosing, treating and surveillance medical disorders. The market for medical devices is changing dramatically. The complicated patient demands and the COVID-19 pandemic encouraged businesses to innovate and produce new creative solutions, and the medical devices industry continued to see exceptional growth in 2020. The global market for medical equipment was worth roughly $456.8 billion in 2020, with a CAGR (Compound annual growth rate) of 3.5{08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f} from 2015. This market is expanding due to the rise in demand for high-tech medical items. There was a fall in the number of diagnoses for various diseases including cancer and TB among others as a result of the COVID-19 epidemic. However, as the pandemic wanes off, the medical device industry is continuing to get back on its growth trajectory.
The frequency of chronic diseases will significantly affect the global medical device market beyond 2022. This encourages the employment of ever-improving technology tools for early disease detection and the creation of intelligent equipment like 3D printing, robots, and the internet of things. As a result, the market for medical device technology will expand at a CAGR of 4.9{08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f} from 2022 to 2027. Growth is predicted from $465.5 billion in 2022 to $591.3 billion in 2027.
Some of the major players in the medical device industry are Boston Scientific Corporation (NYSE:BSX), Medtronic plc (NYSE:MDT), and Abbott Laboratories (NYSE:ABT).
smart.art/Shutterstock.com
Our Methodology
The list includes firms that manufacture medical equipment to treat illnesses. Stocks are presented in order of market capitalization. To offer some different perspective, the analyst ratings of these companies and the most recent information about them are also reviewed. Finally, the number of hedge funds with positions in each company was determined using data from 920 elite hedge funds that Insider Monkey analyzed in the third quarter of 2022.
Globus Medical, Inc. (NYSE:GMED) sells healthcare products and services to hospitals, doctors’ offices, and surgical centers. Globus Medical, Inc. (NYSE:GMED) shares have offered investors more than 6.71{08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f} in returns over the past month as of November 18.
Globus Medical, Inc. (NYSE:GMED) is rated 15th among the world’s biggest medical device companies, with a market value of $6.84 billion. On October 17, Barclays analyst Matt Miksic initiated coverage of Globus Medical, Inc. (NYSE:GMED), assigning the stock an ‘Overweight’ rating and a $69 price target.
At the end of the third quarter, 20 hedge funds in Insider Monkey’s database of 920 funds held stakes in Globus Medical, Inc. (NYSE:GMED) compared to 21 funds in the second quarter. Like Boston Scientific Corporation (NYSE:BSX), Medtronic plc (NYSE:MDT), and Abbott Laboratories (NYSE:ABT), Globus Medical, Inc. (NYSE:GMED) is one of the elite medical device stocks to monitor.
Here is what Madison Small Cap Fund has to say about Globus Medical, Inc. (NYSE:GMED) in its Q4 2020 investor letter:
“Healthcare continued its streak of underperformance in the fourth quarter. The biotech industry component of the Russell 2000 was up 34{08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f} for the quarter and 53{08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f} for the year. While we have become more open to investing in this space where appropriate, we prefer molecular diagnostics given less regulatory risk and better revenue diversification. With the new administration comes a shift in healthcare philosophy. We believe that further access to care and coverage expansion will benefit some parts of the sector. However, the risk of further reimbursement cuts, particularly in pharmaceuticals, will bear monitoring.….” (Click here to read the full text)
Penumbra, Inc. (NYSE:PEN) is a medical device company that manufactures products for the neurovascular and peripheral vascular industries. Penumbra, Inc. (NYSE:PEN) announced the launch of the latest REAL y-Series on November 15. Since it employs a whole body picture, it is the first hands-free, non-tethered virtual reality rehabilitation platform that can treat both the upper and lower extremities.
RBC Capital analyst Brandon Henry boosted his price objective on Penumbra, Inc. (NYSE:PEN) to $215 from $195 on November 14 and reiterated an ‘Outperform’ rating on the stock. According to the analyst, the Q3 results caused the stock to rise 13{08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f} in November.
Among the hedge funds tracked by Insider Monkey, 27 reported owning stakes worth $549.89 million in Penumbra, Inc. (NYSE:PEN) at the end of September 2022, compared to 21 funds in the prior quarter worth $224.66 million. Rock Springs Capital Management is the most notable stakeholder of the company, with nearly 476,000 shares worth $90.25 million.
ClearBridge Investments mentioned Penumbra, Inc. (NYSE:PEN) in its Q4 2021 investor letter. Here is what the fund said:
“Our aversion toward early-stage biotech proved productive as did our approach of emphasizing the enablers and selected, profitable medical technology companies. Strong contributors during the fourth quarter included Penumbra, a developer of stents and related products to treat aneurysms that saw it shares recover from a product recall earlier in the year.”
ShockWave Medical, Inc. (NADAQ:SWAV) is focused on designing and marketing products that will transform how calcified cardiovascular disease is treated. Calcified plaque is treated using the business’s intravascular lithotripsy method.
On November 8, Wells Fargo analyst Larry Biegelsen raised his price target on ShockWave Medical, Inc. (NADAQ:SWAV) from $255 to $300 and reiterated an ‘Overweight’ rating on the stock in light of the company’s improved 2022 projection and Q3 outperformance.
According to Insider Monkey’s data, 34 hedge funds were long ShockWave Medical, Inc. (NADAQ:SWAV) at the end of the third quarter of 2022, compared to 27 funds in the prior quarter. Jim Simons’ Renaissance Technologies held the biggest stake in the company, with approximately 322,700 shares valued at $89.73 million.
“ShockWave Medical, Inc. (NASDAQ:SWAV) is an early stage medical device company developing and commercializing products to treat calcified cardiovascular disease. The company’s recent quarter of +116{08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f} YoY revenue growth was well ahead of expectations. The beat was driven primarily by the C2 coronary intravascular lithotripsy catheter—used to break up hard materials that restrict blood flow to the heart—as it makes solid progress capturing share from stenting cases. We believe the profit cycle opportunity for C2 is meaningful given its large addressable market ($4 billion).”
Bruker Corporation (NASDAQ:BRKR) manufactures scientific equipment and diagnostic tests for the life sciences, pharmaceutical, and biotechnology sectors. The company’s four operational sectors are Bruker BioSpin Group, Bruker Calid Group, Bruker Scientific Instruments Nano, and Bruker Energy & Supercon Technologies. On October 21, UBS analyst John Sourbeer initiated coverage of Bruker Corporation (NASDAQ:BRKR), rating the stock as ‘Buy’ and a price objective of $70.
On November 14, Bruker Corporation announced the execution of a formal agreement to acquire all of Neurescence Inc.’s shares for concurrent multi-region, optical functional neuroimaging. The biotechnology company Neurescence Inc. is a creative manufacturer of portable fiber-bundle multi-scope.
At the end of the third quarter, 28 hedge funds in Insider Monkey’s database held stakes in Bruker Corporation (NASDAQ:BRKR), compared to 25 funds in the second quarter. Millennium Management, with 1.44 million shares, is the most significant stakeholder in the company.
Smith & Nephew plc (NYSE:SNN) develops, produces, and sells orthopedic devices, arthroscopic and sports medicine technology, and wound-care products. The ROCE for Smith & Nephew plc (NYSE:SNN) stands at 9.0{08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f}. Although it’s a poor return in absolute terms, it’s close to the 9.9{08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f} industry average for medical equipment.
Robert Davies, an analyst at Morgan Stanley, initiated coverage of Smith & Nephew plc (NYSE:SNN) on October 18, rating the stock as an ‘Equal Weight’ and a 1,229 GBp price objective.
According to the third quarter database of Insider Monkey, 12 hedge funds were bullish on Smith & Nephew plc (NYSE:SNN). The stakes of these funds are valued at $92.13 million. Peter Rathjens, Bruce Clarke and John Campbell’s Arrowstreet Capital is the most prominent position holder in the company, with approximately 1.74 million shares worth $40.31 million.
Here is what Palm Valley Capital Management has to say about Smith & Nephew plc (NYSE:SNN) in its Q3 2022 investor letter:
“We bought Smith & Nephew plc (NYSE:SNN) toward the end of the quarter. Smith & Nephew is a Londonbased medical device company that specializes in knee and hip replacements, sports medicine, and wound management. We purchased the ADR, which has declined meaningfully (-31{08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f} year-to-date) along with the British pound. While Smith & Nephew’s stock is priced in pounds, its revenues are in other major currencies, such as the dollar, euro, and yen. In 2021, 51{08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f} of its revenues were generated in the United States, while 31{08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f} were in other developed markets. We believe Smith & Nephew is a high-quality business that generates above average profit margins and abundant free cash flow. We were pleased the turmoil in the British pound provided us with the opportunity to purchase its shares at a discount to our calculated valuation.”
Bio-Rad Laboratories, Inc. (NYSE:BIO) currently has an $11.75 billion market capitalization and is placed tenth on the list of the 15 biggest medical device companies in the world. The company is located in Hercules, California, and it develops, produces, and markets clinical diagnostics and life sciences products and solutions.
On August 24, Credit Suisse analyst Dan Leonard initiated coverage of Bio-Rad Laboratories, Inc. (NYSE:BIO), assigning the stock an ‘Outperform’ rating and a $715 price target. The analyst had positive opinions on both the digital PCR, or dPCR, product cycle and the company’s forecasts for margin growth.
By the end of the third quarter, Insider Monkey found Bio-Rad Laboratories, Inc. (NYSE:BIO) to be a part of 45 hedge fund portfolios, compared to 43 positions in the previous quarter. Israel Englander’s Millennium Management is the company’s largest stakeholder, with 458,645 shares worth over $191.32 million.
Align Technology, Inc. (NASDAQ:ALGN) is the maker of transparent dental aligners. In addition, the firm makes intraoral scanners (iTero), which are utilized in orthodontic therapy and restorative dental operations. According to the third quarter database of Insider Monkey, 38 hedge funds were long Align Technology, Inc. (NASDAQ:ALGN), compared to 33 funds in the prior quarter.
On October 27, Baird analyst Jeff Johnson maintained an ‘Outperform’ rating on Align Technology, Inc. (NASDAQ:ALGN) and reduced his price objective to $260 from $310. The analyst attributed the company’s issues to this year’s economic turbulence and last year’s unfavorable stimulus-spending comparison.
Brian Bares’ Bares Capital Management is the most prominent position holder in Align Technology, Inc. (NASDAQ:ALGN), with approximately 913,324 shares worth $189.16 million.
Polen Capital mentioned the company in its Q2 2022 investor letter. Here is what the fund said:
“Align Technology shares declined significantly during the second quarter when management reported a meaningful deceleration in growth. Management cited a host of challenges, including COVID19 impacts, especially in China with restrictions and lockdowns under their zero-COVID policy, a weaker economic environment, inflationary pressures, supply chain disruptions, and the war in Ukraine, to name a few. Tough comparisons were also a reality— Invisalign case starts in 1Q22 were roughly flat, having lapped the 66{08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f} growth from the prior year. It’s not completely surprising that growth is slowing on such tough comparisons, but the company’s shares declined on the news..….” (Click here to read the full text)
Abiomed, Inc. (NASDAQ:ABMD) is a company that conducts research, develops, and sells medical devices that help or take the place of a failing heart’s pumping action. The company offers the Impella CP, a tool used by cardiac surgeons and interventional cardiologists to help patients in cath labs, and the Impella 2.5, a percutaneous micro heart pump with an inbuilt motor and sensors.
Following the declaration that Johnson & Johnson (NYSE:JNJ) has acquired all the outstanding shares of Abiomed, Inc. (NASDAQ:ABMD), Morgan Stanley analyst Cecilia Furlong upgraded the stock of Abiomed (ABMD) to ‘Equal Weight’ on November 2 from ‘Underweight’ with a $380 price target, up from $235.
Hedge fund interest in Abiomed, Inc. (NASDAQ:ABMD) increased in September 2022. 34 hedge funds in our database reported owning stakes in the company at the end of the third quarter, compared to 30 in the previous quarter.
Insulet Corporation (NASDAQ:PODD) manufactures insulin delivery devices for people with diabetes. It provides a wireless companion, portable personal diabetes management, and the Omnipod System. This self-adhesive disposable tubeless Omnipod gadget is worn on the body and is sustainable for up to three days at a time.
Following Insulet Corporation (NASDAQ:PODD)’s Q3 earnings beat and revised FY22 projection, BTIG analyst Marie Thibault increased his price objective on the stock to $320 from $285 on November 11 and retained a ‘Buy’ rating. In addition, as of the end of the third quarter, 39 hedge funds tracked by Insider Monkey had owned stakes in Insulet Corporation (NASDAQ:PODD), compared to just 34 funds in the previous quarter.
In its Q1 2022 investor letter, ClearBridge Investments mentioned Insulet Corporation (NASDAQ:PODD). Here is what the firm said:
“Health care has always been a core foundation of the portfolio and we have been diversifying our health care exposure to include services and solutions beyond our traditional overweight to biopharmaceuticals and managed care. We first purchased Insulet Corporation (NASDAQ:PODD), a leading provider of insulin pumps for diabetes patients, in the fourth quarter of 2021, and we have aggressively added to the position since then. The company is currently the only meaningful manufacturer of patch pumps, the preferred form factor for many patients as compared to traditional tubed pumps. We believe Insulet has a long runway for growth given its large and underpenetrated market, which is only one-third penetrated in Type 1 diabetes and low-single-digit penetrated in the insulin- intensive Type 2 diabetes population. Additionally, we see the launch of the company’s next generation offering, Omnipod 5, which received FDA clearance in January, as an accelerant to growth. Insulet has strong gross margins and is profitable today, though we still see room for significant operating margin expansion ahead.”
Zimmer Biomet Holdings, Inc. (NYSE:ZBH) develops, produces, and sells orthopedic reconstructive implants, orthopedic supplies and surgical equipment. The majority of the reconstructive market in the US, Europe, and Japan is presently owned by Zimmer as a result of the acquisitions of Centerpulse in 2003 and Biomet in 2015.
On November 3, Citi analyst Joanne Wuensch retained a ‘Neutral’ rating on the shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) and cut her price objective from $119 to $116. Wuensch claimed that the orthopedic industry was among the most hit by the pandemic since elective procedures were put off and recovery was challenging.
At the end of the third quarter of this year, 37 hedge funds tracked by Insider Monkey had stakes in Zimmer Biomet Holdings, Inc. (NYSE:ZBH), compared to 41 funds in the previous quarter. Boston Scientific Corporation (NYSE:BSX), Medtronic plc (NYSE:MDT) and Abbott Laboratories (NYSE:ABT) are met by Zimmer Biomet Holdings, Inc. (NYSE:ZBH) in our list of biggest medical devices stocks.
In its Q4 2021 investor letter, Ariel Investments mentioned Zimmer Biomet Holdings, Inc. (NYSE:ZBH). Here is what the fund said:
“A reopening of the global economy with a reduction in the severity of the pandemic has led us to invest in companies that would perform well with an end to Covid restrictions such as canceled sports and entertainment events or companies that would benefit from pent-up demand for consumer products. Healthcare holdings such as Zimmer Biomet Holdings Inc. (ZBH) saw demand for their “elective” healthcare services decline sharply as hospitals lost capacity for non-essential surgeries or orthotics. We believed those companies should see a rebound in their business as cases decline. Unfortunately, two new Covid variants turned this theme from a tailwind to a headwind in the second half of the year. First, Delta then Omicron sent Covid cases higher and both companies saw their businesses slow again. Zimmer’s stock lost -13.04{08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f} in the fourth quarter. As we write, we believe Omicron cases could be nearing a peak which would allow our thesis to better play out this year.”
